June 29, 2017
The malignant lymphoma treatment Adcetris (brentuximab vedotin) hit its primary endpoint of a statistically significant improvement in modified progression-free survival (PFS) against the control group in a multinational PIII study, Takeda Pharmaceutical and Seattle Genetics said on June 27. The...read more